Ex Vivo transduced liver progenitor cells as a platform for gene therapy in mice
β Scribed by Sihong Song; Rafal P. Witek; Yuanqing Lu; Young-Kook Choi; Donghang Zheng; Marda Jorgensen; Chengwen Li; Terence R. Flotte; Byron E. Petersen
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 825 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
Allogeneic stem cell-based transplants may be limited by allograft rejection, as is seen with conventional organ transplantation. One way to avert such a response is to use autologous stem cells, but that may carry the risk of recurrence of the original disease, particularly in the context of a genetic defect. We investigated the potential for gene modification of autologous stem cells to avoid both problems, using recombinant adenoassociated virus vector expressing human al-antitrypsin in murine liver progenitor cells. We showed that recombinant adenoassociated virus 1 was the most efficient vector for liver progenitor cell transduction among five different serotypes of recombinant adenoassociated virus vectors. Ex vivo infected green fluorescent protein-positive liver progenitor cells from C57BL/6 mice with recombinant adenoassociated virus 1-vector-expressing human a1 antitrypsin were transplanted into the liver of monocrotaline-treated and partial-hepatectomized C57BL/6 recipients. Using green fluorescent protein as a donor marker, we were able to determine that at 18 weeks after transplantation, approximately 40% to 50% of the regenerated liver was green fluorescent protein positive. In addition, transgene expression (serum human al-antitrypsin) was sustained for the length of the study (18 weeks after transplantation). Immunostaining revealed approximately 5% to 10% of repopulating liver cells expressing human al-antitrypsin. In conclusion, this study demonstrated the feasibility of long-term engraftment and stability of transgene expression from genetically modified liver progenitor cells with a recombinant adenoassociated virus vector and implies a novel approach to gene therapy for treatment of liver diseases, such as al-antitrypsin deficiency. (HEPATOLOGY 2004; 40:918-924.) al-Antitrypsin (AAT), a serine proteinase inhibitor, is normally secreted from hepatocytes and circulates in plasma, protecting lung elastin from degradation by neutrophil elastase and related proteases. Deficiency of AAT can lead to pan-acinar emphysema resulting from destruc-Abbreviations: AA K cY1-antiqpsin; rAAK recombinant adenoassociated virus; GFP, green~uorescent protein.
π SIMILAR VOLUMES
## Abstract ## Background Bone loss in osteoporosis is caused by an imbalance between resorption and formation on endosteal surfaces of trabecular and cortical bone. We investigated the feasibility of increasing endosteal bone formation in mice by __ex vivo__ gene therapy with bone marrow stromal
## Abstract Cultivation of primary human liver cells in innovative 3D perfusion multiβcompartment capillary membrane bioreactors using decentralized mass exchange and integral oxygenation provides in vitro conditions close to the physiologic environment in vivo. While a few scaleβup bioreactors wer